Breast Cancer


This study will examine the efficacy and safety of trastuzumab deruxtecan compared with trastuzumab emtansine in high-risk patients with residual invasive breast cancer following neoadjuvant therapy.

Trial overview


Breast cancer


A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study Of Trastuzumab Deruxtecan (T-Dxd) Versus Trastuzumab Emtansine (T-Dm1) In Subjects With High-Risk Her2-Positive Primary Breast Cancer Who Have Residual Invasive Disease In Breast Or Axillary Lymph Nodes Following Neoadjuvant Therapy.

Eligibility criteria

Early Her2+ breast cancer with residual disease at surgery.

Study details

Treatment is T-Dxd vs T-Dm1 comparing them directly which treatment is better. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.

Further information

For more regarding this clinical trial click here.


Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.